Relmada Therapeutics, Inc. Appoints Christopher W. James As Senior Director of Clinical Development
Drug Development Team Now Complete and Fully Focused on Clinical Trial Implementation
NEW YORK, Sept. 18, 2014 /PRNewswire/ -- Relmada Therapeutics, Inc., (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that it has appointed Mr. Christopher W. James to the position of Senior Director of Clinical Development.
During his extensive career in Clinical Research, Mr. James has established and led successful global clinical operations teams, in the US and Europe, to facilitate the clinical development of numerous therapeutics and diagnostics across a broad spectrum of therapeutic areas including CNS and psychiatric therapies. He was involved in the evaluation of a mu opioid antagonist for the treatment of opioid induced bowel dysfunction in chronic pain patients. Over the past twenty five years, he has been directly involved in the clinical development of investigational pharmaceutical and biologic products for both early stage and established pharmaceutical companies. In addition to the broad range of therapeutics areas of study, he has diverse experience with various delivery systems, including oral, intravenous, transdermal patch and nasal sprays.
Sergio Traversa, CEO of Relmada Therapeutics, said, "Management is extremely pleased with the addition of Christopher James to our company. He has a proven track record of successfully facilitating the development of investigational products from pre-clinical development through post marketing in a timely and cost-efficient manner. Chris brings to Relmada a formidable background and expertise that we believe will facilitate our clinical trials across the board. In particular, his experience with analgesic research will be of immense value as we develop our pipeline of pain treatments."
James said, "I am very pleased to be joining Relmada at this exciting time in the development of the company. I know that my training and background will be put to good use, and I am very impressed with their pipeline of drugs as it currently stands. I look forward to helping them bring these treatments through the regulatory process and to patients who need them."
About Relmada Therapeutics, Inc.
Relmada Therapeutics is a clinical stage, public specialty pharmaceutical company, focused on developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of pain. The Company has a diversified portfolio of four lead products at different stages of development and a deep early stage pipeline. The Company's product development efforts are guided by the internationally recognized scientific expertise of its research team with inputs from a world-class scientific advisory board. The Company's approach is expected to reduce overall clinical development risks and costs while potentially delivering valuable products in areas of high unmet medical needs.
This news release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Visit our website at, www.relmada.com
SOURCE Relmada Therapeutics, Inc.
Released September 18, 2014